Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 6Idarubicin 4Vorinostat 3Tretinoin 3Etoposide 3Daunorubicin 3Azacitidine 3romidepsin 2Thioguanine 2Sorafenib 2Radiotherapy 2Mitoxantrone 2Methotrexate 2Mercaptopurine 2Lenalidomide 2Cyclophosphamide 2sargramostim 1perifosine 1octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate 1merphos 1ispinesib 1flt3 ligand protein 1entinostat 1belinostat 1Peripheral Blood Stem Cell Transplantation 1Homoharringtonine 1Filgrastim 1Drug Therapy 1Decitabine 1CK0238273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Promyelocytic, Acute × Homoharringtonine × Clear all
NCT00030355 2013-03-22

Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡